Peptides for Brain Fog & Cognitive Health
Brain fog is one of the most frustrating experiences of modern life — and one of the hardest to explain to a doctor. The inability to think clearly, maintain focus, retrieve memories efficiently, or feel mentally sharp sits in a clinical grey zone: real and debilitating for the person experiencing it, but often unaddressed by conventional medicine beyond "sleep more and reduce stress."
Several peptides have attracted serious research interest for their effects on neurological function — particularly two compounds developed in Russia that have decades of research, clinical use, and an increasingly international following: Semax and Selank. This guide covers what they are, how they work, what the evidence shows, and — critically — the important warning about one peptide in this space whose foundational research was retracted for data fabrication in 2025.
Key Takeaways
- Semax is a synthetic ACTH analogue with documented BDNF-upregulating and neuroprotective effects. Approved in Russia since 1994 for stroke and cognitive disorders. Administered intranasally. No FDA approval, but used clinically in the US under physician oversight.
- Selank is a synthetic anxiolytic peptide that improves cognitive function by reducing anxiety-related neural interference. Approved in Russia for anxiety disorders. Removed from FDA Category 2 in September 2024 — its regulatory status in the US is currently being reviewed.
- Cerebrolysin is the only cognitive peptide with multiple large randomised controlled trials in humans (6 RCTs, 784 Alzheimer's patients). IV administration only.
- Dihexa's foundational mechanism paper was formally retracted in April 2025 after an investigation found data falsification. The core claim — that it is "seven orders of magnitude more potent than BDNF" — is based on fabricated data. Its clinical derivative also failed a 312-patient Alzheimer's trial.
- No peptide has been proven to prevent dementia in at-risk populations. All existing human evidence addresses treatment of existing impairment, not prevention.
What Causes Brain Fog
Effective evaluation of any cognitive-enhancing intervention requires understanding that "brain fog" is not a single phenomenon — it is a symptom that can arise from multiple distinct biological mechanisms. Different peptides address different mechanisms, which is why matching the compound to the cause matters more than blanket use.
Evidence Rankings: Honest Positioning Before the Deep Dive
Cognitive Peptides Ranked by Human Evidence Quality
Semax: The BDNF-Upregulating Neuropeptide
Semax
Synthetic ACTH(4-7)-PGP analogue — developed by Russian Academy of Sciences, 1980sHow it works: Semax is a synthetic analogue of a fragment of ACTH (adrenocorticotropic hormone) with a stabilising Pro-Gly-Pro tripeptide added to extend its half-life. Its most documented action is upregulating BDNF (brain-derived neurotrophic factor) and its receptor TrkB in the hippocampus — a process that begins within 30 minutes of intranasal dosing. Think of BDNF as the brain's fertiliser: it promotes neuronal survival, supports the formation and strengthening of synaptic connections, and is essential for learning and memory consolidation. Semax essentially amplifies this signal.
Semax also modulates dopamine and serotonin systems, demonstrates neuroprotective effects in ischaemia models (suppressing inflammatory gene expression while activating neurotransmission genes), and has been studied for its ability to form stable complexes with copper ions — a finding with relevance to Alzheimer's disease, where copper-induced amyloid aggregation plays a contributing role.[1]
Evidence: Semax has been in clinical use in Russia since 1994 — a 30-year track record that most non-approved peptides lack. Human studies have confirmed BDNF upregulation and cognitive effects in stroke patients. A functional connectivity study in 52 healthy participants compared Semax and Selank's resting-state effects. The evidence base is more developed than most cognitive peptides, though it does not meet the standard of large independent RCTs. Users most commonly report improvement in focus, memory retrieval, and analytical clarity.
Selank: Calm Without Sedation
Selank
Synthetic heptapeptide derived from tuftsin — anxiolytic with nootropic propertiesHow it works: Selank's mechanism differs fundamentally from Semax. Rather than directly upregulating neurotrophic factors, it works primarily by reducing anxiety-related neural interference — creating the cognitive conditions under which the brain can perform better without being directly stimulated. It modulates GABA-A receptor sensitivity and inhibits enkephalinase — the enzyme that breaks down the body's natural opioid-like anxiolytic peptides (enkephalins). By protecting these endogenous calming peptides from degradation, Selank restores the brain's own anxiety-buffering system rather than imposing a pharmacological effect from outside.
The cognitive enhancement mechanism is therefore indirect but often highly effective for the right patient profile: anxiety and chronic stress create excessive neural excitation that competes with working memory and cognitive processing. When this interference is reduced, cognitive performance often improves dramatically — not because the brain is more stimulated, but because it is less overwhelmed. Selank also modulates serotonin and dopamine systems, contributing to mood stabilisation and motivation without the sedation or dependency concerns associated with benzodiazepines.[2]
Who it suits: Selank is specifically well-matched to patients whose cognitive complaints are rooted in anxiety, stress overload, or constant mental overstimulation — the "can't think straight because my mind won't stop racing" presentation — rather than pure cognitive deficit. For pure focus or neurotrophic support, Semax may be the more appropriate primary compound.
Cerebrolysin: The Most Human-Evidenced Cognitive Peptide
Cerebrolysin
Neurotrophic peptide complex — 6 Alzheimer's RCTs across 784 patientsCerebrolysin is included here because it represents the strongest human evidence for any peptide-based cognitive intervention. Six randomised controlled trials in 784 Alzheimer's patients have produced consistent findings — Cerebrolysin improves or stabilises cognitive function in mild to moderate Alzheimer's disease compared to placebo. This places it in a different evidence category from Semax, Selank, or any other cognitive peptide. Its limitation is practical: IV administration only, which requires clinical setting administration, and it is not FDA-approved for US patients without off-label access through a physician.
Dihexa: A Critical Warning
⚠️ Important: Dihexa's Foundational Research Was Retracted in 2025
Dihexa is widely marketed in peptide and biohacking communities as a cognitive peptide of extraordinary potency — "seven orders of magnitude more potent than BDNF" is the most commonly cited claim. That claim, and the entire mechanistic case for Dihexa's synaptogenic effects, rests on a 2014 paper published in the Journal of Pharmacology and Experimental Therapeutics by Benoist et al.
In April 2025, this paper was formally retracted following an investigation by Washington State University. The retraction notice states that "Figures 1B, 2A/C, and data in the subsequent erratum submission for the article have been found to contain falsified and/or fabricated data." The lead researcher was found solely responsible.
Separately, Athira Pharma — a company founded to commercialise Dihexa-related compounds — paid a $4.07 million settlement in January 2025 to resolve data falsification allegations. Its clinical derivative, fosgonimeton, failed to meet primary and secondary endpoints in a 312-patient Alzheimer's trial (LIFT-AD trial, 2024).
Dihexa may still have some biological activity — it is a real compound that binds HGF (hepatocyte growth factor), and HGF/c-Met signalling does have neurological relevance. But the extraordinary cognitive claims circulating in the nootropic community rest entirely on fabricated data. Every vendor page repeating the "millions of times more potent than BDNF" claim is citing retracted science. The magnitude and specificity of Dihexa's cognitive effects are unvalidated. Additionally, the HGF/c-Met pathway it activates is a known pro-cancer pathway — raising unresolved safety concerns alongside the evidentiary problems.[3]
Side-by-Side Comparison
| Feature | Semax | Selank | Cerebrolysin |
|---|---|---|---|
| Primary mechanism | BDNF upregulation; dopamine/serotonin modulation; neuroprotection | GABA-A modulation; enkephalinase inhibition; anxiety reduction | Exogenous neurotrophic peptides; synaptogenesis support |
| Best cognitive profile | Poor focus, cognitive fatigue, memory impairment, post-injury recovery | Anxiety-driven brain fog, stress-related cognitive interference, mental overstimulation | Alzheimer's disease, moderate dementia; clinical setting only |
| Route | Intranasal spray | Intranasal spray | IV infusion — clinical setting only |
| Strongest evidence | BDNF elevation confirmed in humans; 30 years Russian clinical use; neuroprotection in stroke | Anxiolytic efficacy in human trials; functional connectivity data in healthy subjects | 6 RCTs in 784 Alzheimer's patients — strongest human evidence of any cognitive peptide |
| Human RCTs | Small studies; no large independent RCT | Limited; Russian clinical trials; functional connectivity study | Multiple large RCTs — yes |
| FDA status (US) | Category 2 — not compoundable without review | Removed from Category 2 (Sept 2024); PCAC review pending | Not approved; available via off-label physician access |
| Used together? | Yes — Semax and Selank are frequently used together; complementary mechanisms with no documented interactions | Used independently; IV only | |
The Missing Foundation: Addressing Root Causes First
Cognitive peptides are among the more advanced interventions in the longevity and brain health space. Their value is greatest when they are built on a foundation of optimised sleep, movement, nutrition, and stress management — not used to compensate for deficiencies in those fundamentals.
The reason this matters mechanistically: poor sleep impairs glymphatic clearance (the brain's waste removal system) and suppresses BDNF production — the very signal Semax works to amplify. Chronic stress elevates cortisol, which damages hippocampal neurons and suppresses neurogenesis. Poor metabolic health produces neuroinflammation. If these root drivers are unaddressed, cognitive peptides are swimming against a biological current.
The Evidence-Based Cognitive Protocol Hierarchy
Sleep quality → Exercise (particularly aerobic) → Stress management → Nutrition and metabolic health → Targeted peptide intervention. Addressing the first four reliably improves cognitive function. Peptides amplify the gains on top of that foundation — they do not substitute for it. The most common reason cognitive peptides underperform expectations is that the fundamental drivers of cognitive decline have not been addressed first.
- Semax remains in FDA Category 2 — legal access in the US requires careful navigation with a physician; research-grade sourcing carries quality risks
- Selank's regulatory position in the US is currently in flux following its September 2024 removal from Category 2; confirm current status before use
- Dihexa should be avoided entirely until independent replication of its core claims occurs — the foundational paper was retracted for fabrication
- No peptide has been shown to prevent dementia — existing evidence covers treatment of existing impairment only
- Intranasal administration of any peptide bypasses first-pass metabolism and delivers compound directly to CNS — which means both faster effects and less predictable dosing in some patients
Interested in a comprehensive approach to cognitive health?
Our free quiz helps you understand your options before speaking with a clinician.
Take Our Peptide Plan Quiz →References
- Naletova I, et al. Semax, a Synthetic Regulatory Peptide, Affects Copper-Induced Abeta Aggregation and Amyloid Formation in Artificial Membrane Models. PMC. 2022. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC8855339/
- Glorioso JC. Peptides for Cognitive Enhancement & Dementia Prevention. December 2025. Available from: https://drglorioso.substack.com
- Peptidesexplorer. 12 Nootropic Peptides Ranked by Evidence (2026). March 2026. Including coverage of Dihexa retraction (Benoist et al., April 2025, J Pharmacol Exp Ther). Available from: https://peptidesexplorer.com
- Dolotov OV, et al. Semax, an Analog of ACTH(4-7) with Cognitive Effects, Regulates BDNF and TrkB Expression in the Rat Hippocampus. PubMed. 2006. PMID: 16996037. Available from: https://pubmed.ncbi.nlm.nih.gov/16996037/
- Rehfeld QM, et al. Cognitive effects of Selank and Semax in healthy humans — functional connectivity analysis. As cited in comparative peptide literature, 2024.
- World Anti-Doping Agency. 2026 Prohibited List. Available from: https://www.wada-ama.org/en/prohibited-list
- Retraction Notice. Benoist et al., 2014. Journal of Pharmacology and Experimental Therapeutics. Formally retracted April 2025 following investigation by Washington State University for data fabrication.